A sarcoma is a type of cancer that develops from certain tissues, such as bone or muscle. There are 2 main types of sarcoma: osteosarcoma, which develops from bone, and soft tissue sarcomas. Soft tissue sarcomas can develop from soft tissues such as fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. They can be found in any part of the body. Most of them develop in the arms or legs. They can also be found in the trunk, head and neck area, internal organs, and the area in back of the abdominal cavity (known as the retroperitoneum). Sarcomas are not common tumors, and most cancers are the type of tumors called carcinomas.
Women with recurrent ovarian cancer can be helped by an experimental therapy using a drug already touted for its ability to fight other cancers, a finding that provides hope for improved treatment of this deadly disease.
Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Childhood cancer survivors who are most at risk of developing a second cancer are more likely to smoke than other childhood cancer survivors - reveals a Cancer Research UK study published in the Journal of the National Cancer Institute.
A new study reveals significant racial and ethnic differences in the treatment and survival of patients with soft-tissue sarcomas, a rare but dangerous cancer that begins in muscle, fat, blood vessels or other supporting tissue of the body.
Around half of patients receive radiotherapy as part of their cancer treatment but the dose is limited by the possibility of causing side effects (toxicity) to the normal tissues and organs that surround the tumour.
University of Manchester scientists discussed their research aimed at reducing the side effects of radiotherapy without decreasing its effectiveness at the National Cancer Research Institute conference in Birmingham today (Tuesday 2 October 2007).
The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung.
Soft tissue sarcomas -rare tumours of the connective tissue- should be treated at the few centres which see most cases, in order to give patients the best chance of good outcomes, concludes an analysis of sarcoma management in Florida, published in the Annals of Surgery last month.
The sea-squirt derived drug trabectedin (ecteinascidinin-743) shows anti-tumour activity in more than half of patients with a specific type of cancer, conclude authors of an article published early Online and in the July edition of The Lancet Oncology.
As published in the June 1 issue of Genes & Development, Dr. Leonard Zon (Children's Hospital Boston) and colleagues have identified the cancer stem cell for rhabdomyosarcoma, the most common soft-tissue sarcoma of childhood.
New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers.
Oncolytics Biotech has announced that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN in patients with various sarcomas that have metastasized to the lung.
Treatments for childhood cancer have resulted in a current overall cure rate of over 70 percent. However, long-term survivors of childhood cancer are at a higher risk of developing a secondary cancer than the general population.
A new pilot study suggests that treating soft-tissue sarcoma with a new regimen of intense chemotherapy and a short course of radiation before surgery may be beneficial. About 41 percent of study participants were found to have complete tumor death at the time of surgery.
Counting the amount of a type of normal cell circulating in the blood of people with cancer could predict whether a tumor progresses or responds to therapy, a new study led by the University of Michigan Comprehensive Cancer Center has found. The finding could give doctors an early indication of whether a treatment will be successful, sparing patients months of an ineffective therapy.
A new study has found that although children treated for soft tissue sarcomas are surviving longer than they did in the past, they have an increased risk for second cancers, especially when initial treatment combined radiation and chemotherapy. This is according to analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.
Children treated for soft tissue sarcomas have a significantly higher risk of developing subsequent cancers later in life, according to a new study. The study appears in the June 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society, and indicates children treated with combined chemotherapy and radiation therapy, in particular, had greater risks of developing a new malignancy.
Rhabdomyosarcoma is a highly malignant aggressive form of soft tissue cancer in children, the causes of which are currently unknown. Although the fibrous growths can be found all over the body they commonly develop around the head, neck, bladder and testes in young boys.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.